Literature DB >> 22216497

CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

S I Johannessen1, M Gerna, J Bakke, R E Strandjord, P L Morselli.   

Abstract

Serum and CSF samples of patients receiving chronic carbamazepine treatment were analysed. Daily fluctuations in serum levels of carbamazepine and carbamazepine-10,11-epoxide did not appear to be related to the dosage schedule, but some patients tended to have lower fluctuations when the carbamazepine was given more frequently. The epoxide/carbamazepine serum ratios varied greatly from patient to patient, and also fluctuated during the day for the same patient. Carbamazepine and carbamazepine-10,11-epoxide were present in CSF in concentrations ranging from 19 to 34% and 26 to 71% of the serum concentrations, respectively. There was a significant relationship between the free fraction of both drugs evaluated in vivo and the CSF/serum ratios. The need for a careful evaluation of the possible clinical effect of the epoxide is stressed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 22216497      PMCID: PMC1428922          DOI: 10.1111/j.1365-2125.1976.tb04878.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Drug-protein binding. IV. Modulation of binding. Increasing activity of sulfonamides with displacing agents: a review.

Authors:  A H Anton
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

Review 2.  Influence of binding on drug metabolism and distribution.

Authors:  P G Dayton; Z H Israili; J M Perel
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

Review 3.  Overview of drug-protein binding.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

4.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

5.  Theoretical changes in drug distribution resulting from changes in binding to plasma proteins and to tissues.

Authors:  S H Curry
Journal:  J Pharm Pharmacol       Date:  1970-10       Impact factor: 3.765

6.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

7.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

8.  Imipramine steady-state studies and plasma binding.

Authors:  A H Glassman; M J Hurwic; M Kanzler; M Shostak; J M Perel
Journal:  Adv Biochem Psychopharmacol       Date:  1974

9.  Plasma protein binding of tricyclic anti-depressants in man.

Authors:  O Borgå; D L Azarnoff; G P Forshell; F Sjöqvist
Journal:  Biochem Pharmacol       Date:  1969-09       Impact factor: 5.858

10.  Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy.

Authors:  S I Johannessen; R E Strandjord
Journal:  Epilepsia       Date:  1973-12       Impact factor: 5.864

View more
  11 in total

1.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

2.  Failure of carbamazepine to prevent clonazepam withdrawal status epilepticus.

Authors:  G P Sechi; G Zoroddu; G Rosati
Journal:  Ital J Neurol Sci       Date:  1984-09

3.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

6.  Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey.

Authors:  P J Wedlund; I H Patel; R H Levy
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

7.  Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients.

Authors:  K Ghose; D E Fry; J A Christfides
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice.

Authors:  J M Lancaster; J A Davies
Journal:  Experientia       Date:  1992-08-15

9.  The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients.

Authors:  Chahra Chbili; Anis Hassine; Aicha Laouani; Sana Ben Amor; Manel Nouira; Sofiène Ben Ammou; Saad Saguem
Journal:  Arch Med Sci       Date:  2016-05-20       Impact factor: 3.318

10.  Carbamazepine modulates the spatiotemporal activity in the dentate gyrus of rats and pharmacoresistant humans in vitro.

Authors:  Natalie L M Cappaert; Taco R Werkman; Nuria Benito; Menno P Witter; Johannes C Baayen; Wytse J Wadman
Journal:  Brain Behav       Date:  2016-04-15       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.